Europe’s crop output has grown more slowly than in major agricultural markets including the US, Brazil, China, Canada and India, a new study finds / Geopolitical and climate pressures are increasing risks for farmers while global peers gain …
Vividion Therapeutics Expands Clinical Development of WRN Inhibitor VVD-214 with Phase II Combination Study in First-Line Patients with Advanced Colorectal Cancer
Not intended for UK Media
First patient dosed in global Phase II study evaluating VVD-214, an oral Werner helicase (WRN) inhibitor, plus pembrolizumab in front-line patients with advanced MSI-high or dMMR colorectal cancer / Study broadens clinical development of VVD-214 …
Otto Bayer Award goes to plant researcher Sarah O’Connor / Early Excellence in Science Awards recognize outstanding early-career research in biology, chemistry, medical science and plant science / Plant Science award presented for the first time
U.S. FDA accepts Bayer’s supplemental New Drug Application for finerenone in chronic kidney disease without diabetes
Not intended for U.S. and UK Media
The supplemental New Drug Application (sNDA) was based on the positive Phase III FIND-CKD study results, which demonstrated that finerenone significantly delayed kidney disease progression and reduced cardiovascular-kidney events in addition to …
Company plans to build state-of-the-art site in New Albany, Ohio, U.S., to serve patients in the U.S. as well as globally / Bayer expects to create around 600 new high-value jobs in the area / Multi-year investment reinforces U.S. business …
Bayer appoints Dr. Christoph Koenen, MD, as Chief Medical Officer
Not intended for U.S. and UK Media
Berlin, October 1, 2026 – Bayer today announced the appointment of Dr. Christoph Koenen, MD, as Chief Medical Officer, effective October 1, 2026. He will lead medical and scientific strategies across the organization and assume these …
BlueRock Therapeutics’ investigational cell therapy lemiretprocel (OpCT-001) for primary photoreceptor diseases granted orphan drug designations by FDA and EMA
Not intended for UK Media
U.S. FDA designations are for treating retinitis pigmentosa and cone-rod dystrophy / EU EMA designations are for treating syndromic and non-syndromic inherited retinal disorders (IRDs) of the rod-dominant phenotype and non-syndromic IRDs of the …
Bayer Launches New Menopause Advocacy and Policy Alliance
Not intended for U.S. and UK Media – International Menopause Society (IMS) Congress 2026:
Global leaders in women’s and public health unite to form the Menopause Advocacy and Policy (MAP) Alliance and accelerate menopause care, policy and workplace support / At IMS, the MAP Alliance unveils research that highlights why menopause must …
Bayer’s Lynkuet™ (elinzanetant) granted priority review by U.S. FDA for additional indication
Not intended for U.S. and UK Media
Priority review granted for treatment of moderate to severe vasomotor symptoms (VMS; also known as hot flashes) in women undergoing endocrine therapy for hormone receptor positive breast cancer / LynkuetTM (elinzanetant) also became the first …
Bayer places 2 billion euro hybrid bonds
NOT FOR DISTRIBUTION IN THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA, SOUTH AFRICA OR JAPAN
Dual tranche with non-call periods of six and nine years
New blister receives RecyClass Design for Recycling certification, with phased rollout planned across 11 additional European markets in 2026–2027